Correction: zheng et al. glycolysis-related slc2a1 is a potential pan-cancer biomarker for prognosis and immunotherapy. cancers 2022, 14,

HIGHLIGHTS

  • who: Haosheng Zheng and collaborators from the DepartmentUniversity, Guangzhou, China have published the article: Correction: Zheng et al. Glycolysis-Related SLC2A1 Is a Potential Pan-Cancer Biomarker for Prognosis and Immunotherapy. Cancers 2022, 14,, in the Journal: Cancers 2023, 15, 586. of 10/01/2023

SUMMARY

    Received Published: 18 January 2023 2 of 2 The authors would like to apologize for any inconvenience caused. Zheng, H.; Long, G.; Zheng, Y.; Yang, X.; Cai, W.; He, S.; Qin, X.; Liao, H. Glycolysis-Related SLC2A1 Is a Potential Pan-Cancer Biomarker for Prognosis and Immunotherapy . . .

     

    Logo ScioWire Beta black

    If you want to have access to all the content you need to log in!

    Thanks :)

    If you don't have an account, you can create one here.

     

Scroll to Top

Add A Knowledge Base Question !

+ = Verify Human or Spambot ?